X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Novartis with Cipla - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NOVARTIS vs CIPLA - Comparison Results

NOVARTIS    Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

CIPLA 
   Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NOVARTIS CIPLA NOVARTIS/
CIPLA
 
P/E (TTM) x 346.4 44.7 775.8% View Chart
P/BV x 17.1 3.7 463.3% View Chart
Dividend Yield % 1.7 0.3 485.1%  

Financials

 NOVARTIS   CIPLA
EQUITY SHARE DATA
    NOVARTIS
Mar-16
CIPLA
Mar-17
NOVARTIS/
CIPLA
5-Yr Chart
Click to enlarge
High Rs982622 157.9%   
Low Rs556458 121.4%   
Sales per share (Unadj.) Rs252.9181.9 139.1%  
Earnings per share (Unadj.) Rs62.112.9 482.8%  
Cash flow per share (Unadj.) Rs63.329.3 215.9%  
Dividends per share (Unadj.) Rs10.002.00 500.0%  
Dividend yield (eoy) %1.30.4 351.1%  
Book value per share (Unadj.) Rs363.6155.7 233.6%  
Shares outstanding (eoy) m31.96804.51 4.0%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x3.03.0 102.4%   
Avg P/E ratio x12.442.0 29.5%  
P/CF ratio (eoy) x12.218.4 66.0%  
Price / Book Value ratio x2.13.5 61.0%  
Dividend payout %16.115.5 103.6%   
Avg Mkt Cap Rs m24,580434,516 5.7%   
No. of employees `0000.823.0 3.3%   
Total wages/salary Rs m1,80126,338 6.8%   
Avg. sales/employee Rs Th10,748.96,349.1 169.3%   
Avg. wages/employee Rs Th2,395.21,143.0 209.6%   
Avg. net profit/employee Rs Th2,641.1449.3 587.8%   
INCOME DATA
Net Sales Rs m8,083146,302 5.5%  
Other income Rs m8292,287 36.3%   
Total revenues Rs m8,913148,589 6.0%   
Gross profit Rs m23424,758 0.9%  
Depreciation Rs m3713,229 0.3%   
Interest Rs m21,594 0.1%   
Profit before tax Rs m1,02512,222 8.4%   
Minority Interest Rs m00-   
Prior Period Items Rs m17-70 -23.9%   
Extraordinary Inc (Exp) Rs m1,6960-   
Tax Rs m7521,798 41.8%   
Profit after tax Rs m1,98610,354 19.2%  
Gross profit margin %2.916.9 17.1%  
Effective tax rate %73.414.7 498.8%   
Net profit margin %24.67.1 347.2%  
BALANCE SHEET DATA
Current assets Rs m12,67887,370 14.5%   
Current liabilities Rs m2,43333,081 7.4%   
Net working cap to sales %126.737.1 341.6%  
Current ratio x5.22.6 197.3%  
Inventory Days Days3387 37.6%  
Debtors Days Days2262 36.1%  
Net fixed assets Rs m69111,567 0.1%   
Share capital Rs m1601,609 9.9%   
"Free" reserves Rs m11,460123,645 9.3%   
Net worth Rs m11,621125,254 9.3%   
Long term debt Rs m036,454 0.0%   
Total assets Rs m14,400209,532 6.9%  
Interest coverage x570.58.7 6,581.5%   
Debt to equity ratio x00.3 0.0%  
Sales to assets ratio x0.60.7 80.4%   
Return on assets %13.85.7 242.1%  
Return on equity %17.18.3 206.7%  
Return on capital %23.68.5 277.4%  
Exports to sales %0.734.2 2.2%   
Imports to sales %18.68.3 222.9%   
Exports (fob) Rs m6050,050 0.1%   
Imports (cif) Rs m1,50312,203 12.3%   
Fx inflow Rs m18651,066 0.4%   
Fx outflow Rs m1,82117,678 10.3%   
Net fx Rs m-1,63533,388 -4.9%   
CASH FLOW
From Operations Rs m2,53123,824 10.6%  
From Investments Rs m-8,270-13,127 63.0%  
From Financial Activity Rs m-386-13,239 2.9%  
Net Cashflow Rs m-6,125-2,478 247.2%  

Share Holding

Indian Promoters % 0.0 16.0 -  
Foreign collaborators % 75.0 20.8 360.6%  
Indian inst/Mut Fund % 2.0 12.2 16.4%  
FIIs % 1.6 23.7 6.8%  
ADR/GDR % 0.0 1.1 -  
Free float % 21.5 26.2 82.1%  
Shareholders   41,647 161,166 25.8%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NOVARTIS With:   PFIZER  ABBOTT INDIA  PLETHICO PHARMA  DR. REDDYS LAB  TORRENT PHARMA  

Compare NOVARTIS With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Finishes on a Flat Note; Coal India Stock Rallies 4.2%(Closing)

Indian share markets finished some selling pressure in the final hour of trade to finish flat amid weak European markets.

Related Views on News

Cipla: Operating Margins Improve (Quarterly Results Update - Detailed)

Mar 8, 2017

Cipla has announced its results for the December quarter (1QFY17) results. The company has reported a decline of 6.4% YoY in sales while profits were down by 43.7% YoY.

Cipla: Weak Quarter, Positive Triggers Ahead (Quarterly Results Update - Detailed)

Sep 19, 2016

Cipla has announced its results for the June quarter (1QFY17) results. The company has reported a decline of 6.4% YoY in sales while profits were down by 43.7% YoY.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

More Views on News

Most Popular

Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

Aug 7, 2017

The data tells us quite a different story from the one the government is trying to project.

Proxy Plays: A Smart Way to Bet on 'Off Limits' Companies(The 5 Minute Wrapup)

Aug 4, 2017

The small-cap space is full of small players that are clear proxies to great growth stories and Indian megatrends.

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

Aug 7, 2017

Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

NOVARTIS SHARE PRICE


Aug 17, 2017 (Close)

TRACK NOVARTIS

  • Track your investment in NOVARTIS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NOVARTIS 8-QTR ANALYSIS

COMPARE NOVARTIS WITH

MARKET STATS